Apogee's asthma antibody already showed FeNO cuts; more data due in H2
A 31-patient Phase 1b trial already reported interim FeNO suppression and a favorable safety readout; Apogee plans to add more zumilokibart asthma data at medical conferences by year end.
Executive Summary
- Apogee's asthma cohort has already read out, with an interim biomarker result and a favorable safety profile disclosed months before this event, so the conference presentation is a maturation of existing data rather than a new binary result.
- A positive early signal in asthma would extend zumilokibart's story beyond its lead atopic dermatitis program, supporting the company's stated ambition to position the antibody across multiple inflammatory diseases.
- The trial finished enrollment at its target size and moved cleanly to Active, not recruiting, on schedule, with no signal of a program in distress.
- No competitor trial in the current asthma field shares zumilokibart's target or mechanism class, leaving this drug without a direct precedent to benchmark against inside that indication.
- The fuller dataset expected at conferences later this year will show whether the safety and biomarker signal holds across the complete 31-patient cohort and whether it supports a move into a larger, controlled asthma study.
The event
Apogee Therapeutics said it expects to share additional data from the Phase 1b zumilokibart asthma trial at medical conferences later in 2026, in a pipeline update issued March 2, 2026. The company set the window at July 1 through December 31, 2026. The trial, registered as NCT06920901, is a Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of APG777 (zumilokibart) in adults with mild-to-moderate asthma. Apogee+1Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial ResultsMar 2, 2026A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaNCT06920901
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What already read out
This is not the first data point from the cohort. Apogee disclosed interim Phase 1b results on January 6, 2026, reporting that a single 720 mg dose produced a mean FeNO (a biomarker of airway inflammation) reduction of 45 ppb, a 60% drop from baseline, sustained through 16 weeks, with no Grade 3 or higher treatment-emergent adverse events or serious adverse events and gastroesophageal reflux reported in two patients. Chief Executive Officer Michael Henderson said the company made "progress across our pipeline, including advancing zumilokibart with positive APEX Phase 2 Part A results, as well as proof-of-concept data from our Phase 1b trial in asthma". The registered primary endpoints for this trial are safety measures: the number of participants with abnormal ECGs, abnormal laboratory findings, abnormal physical exams, abnormal vital signs, and treatment-emergent adverse events. Apogee+1Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial ResultsMar 2, 2026A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaNCT06920901
Trial status
The trial enrolled to its target of 31 patients and moved from Recruiting to Active, not recruiting on September 9, 2025, with the anticipated enrollment count revised from 32 to 31 patients on the same date, a change within the routine band the operational model uses to flag enrollment shifts. The trial carries a primary completion date of September 1, 2026, and an overall study completion date of March 1, 2027. Registry amendment activity has been limited to that single status and enrollment update since the trial's initial posting in April 2025. NCT06920901A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaNCT06920901
Competitive field
No trial in the current asthma competitive field shares zumilokibart's target or mechanism class, leaving the asset without a direct comparator inside this indication. The nearest neighbors identified across the broader indication landscape, including benralizumab, depemokimab, and stapokibart, work through different interleukin or IgE-pathway mechanisms and sit mostly in chronic obstructive pulmonary disease rather than asthma itself. Apogee's own guidance frames the asthma program as an expansion indication behind its lead zumilokibart trials in atopic dermatitis, where a Phase 2 maintenance readout and a planned Phase 3 initiation in the second half of 2026 carry more weight for the company's broader inflammatory-disease strategy. ApogeeApogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial ResultsMar 2, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.